Related references
Note: Only part of the references are listed.The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19
Alexander P. J. Vlaar et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland
Matthias Peter Hilty et al.
INTENSIVE CARE MEDICINE (2022)
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19
Sistiana Aiello et al.
BLOOD ADVANCES (2022)
In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality
Aditya Shah et al.
ANNALS OF INTERNAL MEDICINE (2022)
The state of complement in COVID-19
Behdad Afzali et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
I. O. Rosas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population
Farhan S. Cyprian et al.
FRONTIERS IN IMMUNOLOGY (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
Clinical features and prognostic factors in Covid-19: A prospective cohort study
Sanne de Bruin et al.
EBIOMEDICINE (2021)
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis
Manu Shankar-Hari et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
S. J. Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Complement inhibition in severe COVID-19-Blocking C5a seems to be key
Endry H. T. Lim et al.
ECLINICALMEDICINE (2021)
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review
W. Joost Wiersinga et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis
Julien Carvelli et al.
NATURE (2020)
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Alexander P. J. Vlaar et al.
LANCET RHEUMATOLOGY (2020)
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study
Djillali Annane et al.
ECLINICALMEDICINE (2020)
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition
Niels C. Riedemann et al.
CLINICAL IMMUNOLOGY (2017)
The Nature of the P Value
Daniel Hu
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys
Shihui Sun et al.
CLINICAL INFECTIOUS DISEASES (2015)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)